Hurry, ends in:


Impact Peptide 1.3 Immunonutrition Supplement - Unflavored 250 mL Tetra Prisma®

169 565913 03
110 Guarantee

Price Guarantee

Shop with confidence and know you're getting a great deal! However, if you find a lower price (including shipping) on another website, we'll match it. Just call or email us, either before you've made your purchase or within 30 days after your purchase. Some restrictions apply. Read our Best Price Guarantee for complete details.

1-800-861-3211 or Contact Us online.

Ships from warehouse. Est. Ship Date Dec. 12, 2023

Estimate Price
Compare offers The Impact Peptide 1.3 Immunonutrition Supplement. Immunonutrition is for surgical and trauma patients with a balanced peptide profile and 50% of fat as MCT to support absorption and tolerance. Impact ® Peptode 1.5 formula has been designed to combine the absorption and tolerance benefits of CRUCIAL® with the medical evidence of IMPACT® 1.5.



  • Contains immune-modulating ingredients supported by the 2009 Critical Care Nutrition Guidelines1*
  • Only IMPACT® formulas contain the unique immunonutrient blend of arginine, omega-3 fatty acids and dietary nucleotides clinically proven to support improved immune response.
  • Offers the same unique evidence based blend of immunonutrients associated with positive outcomes observed for other IMPACT family formulas when fed early in surgery and critical care patients, including: decreased risk of infectious complications, decreased LOS and decreased ventilator days. 
  • Balanced peptide profile to facilitate nitrogen absorption and utilization.

Lipid profile: 

  • 50% MCT to support absorption and tolerance
  • Support the modulation of pro-inflammatory mediators
  • Macro- and micronutrient profiles designed to support wound management 
  • Available in 250 mL Tetra Prisma® and 1000 mL ULTRAPAK® with SPIKERIGHT®



More Information
Brand Name Invacare® Supply Group
Manufacturer Number 4390097400
Write Your Own Review


Ask Question

Ask Question

All questions will be displayed after moderation.

No questions yet. Be the first to ask the question!